FH-2494

N/A

Report date: 2023/05/05 17:34:27

Base Information

Drug NameFH-2494

Drug Alias NameFH-2494

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy

Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsT lymphocyte replacements

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsLymphoma, Mantle-CellLymphoma, FollicularLymphoma, Large B-Cell, Diffuse +[6]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesFred Hutchinson Cancer Research Center National Cancer Institute

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesNational Cancer Institute Fred Hutchinson Cancer Research Center

Active IndicationsN/A

Inactive IndicationsLymphoma, Mantle-CellLymphoma, FollicularLymphoma, Large B-Cell, Diffuse +[6]

Other Information

ATC CodeN/A